The Angiogenesis Foundation
| Company type | Non-profit |
|---|---|
| Founded | 1994 in Cambridge, MA |
| Founder | William W. Li, MD and Vincent W. Li, MD (co-founders) |
| Headquarters | Cambridge, MA, U.S. |
| Revenue | 1,772,286 United States dollar (2017)  |
| Total assets | 359,298 United States dollar (2022) |
| Website | angio.org |
The Angiogenesis Foundation, is a United States 501(c)(3) nonprofit organization established in 1994 for the study of angiogenesis. The foundation developed a therapy for canine cancer, called the Navy Protocol. This treatment works by starving the tumor of its blood supply.[1] In 2004, they helped publicly launch the first antiangiogenic therapy for cancer, bevacizumab, starting with colorectal cancer.[2]
Co-founder Dr. William Li won the 2024 Dr. Andrew von Eschenbach Award for his work in angiogenesis.[3]
References
[edit]External links
[edit]- Official website
- "The Angiogenesis Foundation Receives Highest Rating from Charity Navigator" - The Providence Journal, Nov. 7, 2013.
 | This article about a medical organization or association is a stub. You can help Wikipedia by expanding it. |